Abstract
Considerable controversy continues over the optimal hematocrit target for dialysis patients being treated with recombinant erythropoietin. Recent short-term studies have demonstrated a significant improvement in brain function when hematocrit is 42% compared with when it is 31%. Questions regarding the safety of long-term maintenance of a normal hematocrit have been raised; however, this is in part because of the early termination of the Normal Hematocrit Cardiac Trial, in which there was an increased occurrence of death or nonfatal myocardial infarction in patients randomly assigned to the normal hematocrit group. For the present, a target hematocrit of 36% seems reasonable and safe.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
